Page 1

Boston Scientific Boston Scientific Announces Results For First Quarter 2021 MARLBOROUGH , Mass . , April 28 , 2021 / PRNewswire / -- Boston Scientific Corporation ( NYSE : BSX ) generated net sales of $ 2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis , 5.6 percent on an operational¹ basis and 5.9 percent on an organic basis , all compared to the prior year period . The company reported GAAP net income available to common stockholders of $ 327 million or $ 0.23 per share ( EPS ) , compared to GAAP net income of $ 11 million or $ 0.01 per share a year ago , and achieved adjusted EPS of $ 0.37 for the period , compared to $ 0.28 a year ago . " We are pleased by the trajectory of our recovery , " said Mike Mahoney , chairman and chief executive officer , Boston Scientific . " Our global team remains committed to helping patients and our customers by delivering a robust portfolio of innovative solutions , and that commitment will continue to fuel our future growth . " First quarter financial results and recent developments : • Reported net sales of $ 2.752 billion , representing an increase of 8.2 percent on a reported basis , compared to the company's guidance range of 0 to 6 percent ; 5.6 percent on an operational basis ; and 5.9 percent on an organic basis , compared to the company's guidance range of ( 3 ) to 3 percent , all compared to the prior year period . • Reported GAAP net income available to common stockholders of $ 0.23 per share compared to the company's guidance range of $ 0.05 to $ 0.11 per share . Achieved adjusted EPS of $ 0.37 compared to the guidance range of $ 0.28 to $ 0.34 per share . • Achieved net sales growth in each reportable segment , compared to the prior year period : ⚫ MedSurg : 11.1 percent reported , 8.6 percent operational and 9.5 percent organic ⚫ Rhythm and Neuro : 6.8 percent reported , 4.0 percent operational and 1.6 percent organic ⚫ Cardiovascular : 10.0 percent reported , 7.4 percent operational and organic • Achieved the following regional net sales growth , compared to the prior year period : ⚫ U.S .: 8.6 percent reported and operational ⚫ EMEA ( Europe , Middle East and Africa ) : 9.4 percent reported and 1.9 percent operational 。 APAC ( Asia - Pacific ) : 15.6 percent reported and 9.1 percent operational Emerging Markets³ : 16.0 percent reported and 13.2 percent operational • Received U.S. Food and Drug Administration ( FDA ) approval for the TheraSphere ™ Y - 90 Glass Microspheres for the treatment of patients with hepatocellular carcinoma , the most common type of primary liver cancer , and secured FDA Breakthrough Device designation for TheraSphere treatment for patients with glioblastoma , a type of brain cancer.6 • Received approval for the Ranger ™ Drug - Coated Balloon from Japan's Ministry of Health , Labor and Welfare ( MHLW ) and initiated a full launch in the region . • Launched Vercise Genus ™ Deep Brain Stimulation ( DBS ) System in the U.S. Additionally , the system is being used with the world's first 16 - channel directional leads - Cartesia TM X and HX leads- in the eXTend 3D Study in Europe . • Commenced U.S. launch of the WaveWriter Alpha ™ portfolio of spinal cord stimulator ( SCS ) systems , consisting of four full - body MR conditional , Bluetooth - enabled devices , newFAST paresthesia- free therapy and all supported by Cognita ™ Solutions - a suite of digital tools that helps physicians and patients navigate the pain management journey . ⚫ Surpassed 50,000 patients worldwide treated with the SENTINEL ™ Cerebral Protection System , the first and only FDA - cleared device to protect patients from stroke risk during transcatheter aortic valve replacement ( TAVR ) procedures . ⚫ Published positive 12 - month results from the PINNACLE FLX clinical trial in Circulation , demonstrating the next - generation WATCHMAN FLX ™ Left Atrial Appendage Closure ( LAAC ) Device is a safe and effective alternative to oral anticoagulation therapy for stroke risk reduction in patients with non - valvular atrial fibrillation and increased risk of bleeding . The trial met its primary safety endpoint with a low adverse event rate of 0.5 % , as well as its primary effectiveness endpoint with a 100 % rate of LAA closure at 12 months . • Presented five - year outcomes from the EFFORTLESS study , the largest post - market registry of the Subcutaneous Implantable Defibrillator ( S - ICD ) System , further validating the long - term efficacy of the device . Results demonstrated 98 % overall efficacy over five years , consistent with results of previous S - ICD studies and comparable to or higher than many large transvenous ICD studies . • Received FDA approval to modify the design of the ACURATE IDE trial - evaluating the ACURATE neo2 ™ Aortic Valve System - to an " all - risk " protocol to study patients with severe , symptomatic aortic stenosis who are at low risk of open - heart surgery , in addition to those at intermediate , high and extreme risk . • Initiated the NEWTON AF IDE clinical trial to evaluate the safety and effectiveness of the NTELLANAV STABLEPOINT ™ Ablation Catheter enabled with DIRECTSENSE ™ Technology in patients with paroxysmal atrial fibrillation . • Named eighth on the Forbes list of America's Best Employers for Diversity 2021 , based on a survey of 50,000 Americans working for businesses with at least 1,000 employees . • Completed the acquisition of Preventice Solutions , Inc. , a privately - held company which offers a full portfolio of mobile cardiac health solutions and services , for an upfront cash payment of $ 720 million , with up to an additional ~ $ 230 million in a potential commercial milestone payment , given a preexisting 22 percent equity stake . Completed the sale of the BTG Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS , affiliates of SERB , for $ 800 million in cash . • Announced a definitive agreement with an affiliate of Baring Private Equity Asia to acquire the global surgical business of Lumenis LTD . , a privately - held company that develops and commercializes energy - based medical solutions , for an upfront cash payment of ~ $ 1.07 billion , subject to customary closing conditions and adjustments . • Announced plans to host a virtual Investor Day business review meeting for the investment community on Wednesday , September 22 , 2021 . 1. Operational net sales growth excludes the impact of foreign currency fluctuations . 2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales from the recent acquisition of Preventice Solutions , Inc. ( Preventice ) . Organic net sales growth rates also exclude the intrauterine health franchise , which we divested in Q2 2020 and the Specialty Pharmaceuticals business , which we divested in Q1 2021 .